FDA Committee Vote on Peptides
An FDA committee voted to increase access to six of seven peptides.
1Health & Policy
FDA Committee Votes to Expand Access to Popular Peptides
A recent FDA committee vote aims to increase access to six of seven peptides, substances often promoted on social media for physical transformations.
Listen to the source episode
Why Peptides Could Become More Accessible in the U.S.
Continue in GenPod
Turn this episode into your next question.
Ask naturally. GenPod can find a related episode—or make a focused explainer when the right one does not exist.Key takeaways
What to know before you press play.
Ask GenPod next
Keep the question moving.
“What are the specific health benefits of peptides?”
“How does the FDA regulate peptides?”
“What other health trends are emerging in the U.S.?”
Background reading
The context behind the episode.
Context
Regulatory Landscape for Peptides
Peptides are substances that have not undergone regulatory approval but are widely promoted on social media for physical transformations like better skin.
2Questions
Questions to carry into the episode.
Experts
Voices named in the source.
Alex Janin
WSJ health and wellness reporter
3Sources and disclosure
Where this guide comes from.
This guide is based on the WSJ What’s News episode 'Why Peptides Could Become More Accessible in the U.S.' published on 2026-07-24.
- Publisher show notes
Today an FDA committee voted to increase access to six of seven peptides.
- Publisher show notes
Those are substances that haven’t undergone regulatory approval, but they’re promoted on social media and promise physical transformations like better skin.
- Publisher show notes
We hear from WSJ health and wellness reporter Alex Janin about what the vote means and whether it paves the way for a peptide gold rush.
- Publisher show notes
Plus, new tariffs went into effect today intended to combat forced labor, and President Trump also threatened new tariffs on the European Union.
- Publisher show notes
Journal trade and economic policy reporter Gavin Bade discusses the future of President Trump’s tariff agenda.
- Publisher show notes
And measles cases in the U.S. this year have already surpassed last year’s number, reaching a three-decade high.
- Publisher show notes
And for more on peptides, listen to our What’s News Sunday episode.
- Publisher show notes
Sign up for the WSJ's free What's News newsletter.
- Publisher show notes
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Related listening guides